These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 11049795)

  • 21. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.
    Hunt PW; Harrigan PR; Huang W; Bates M; Williamson DW; McCune JM; Price RW; Spudich SS; Lampiris H; Hoh R; Leigler T; Martin JN; Deeks SG
    J Infect Dis; 2006 Oct; 194(7):926-30. PubMed ID: 16960780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
    Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
    J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of hydroxyurea in heavily pretreated patients with HIV infection.
    Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N
    Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The V118I mutation as a marker of advanced HIV infection and disease progression.
    Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
    Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute human immunodeficiency virus type 1 infection.
    Kahn JO; Walker BD
    N Engl J Med; 1998 Jul; 339(1):33-9. PubMed ID: 9647878
    [No Abstract]   [Full Text] [Related]  

  • 26. [Quantitation of human immunodeficiency virus type 1 RNA by ultrasensitive method in the analysis of samples with low viral load].
    Nishida Y; Moriya K; Nagaizumi K; Inaba H; Amano K; Fukue H; Yamamoto Y; Arai M; Fukutake K
    Rinsho Byori; 2000 Mar; 48(3):282-3. PubMed ID: 10804838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.
    Wirden M; Marcelin AG; Tubiana R; Valantin MA; Ghosn J; Duvivier C; Dominguez S; Paris L; Agher R; Peytavin G; Katlama C; Calvez V
    J Acquir Immune Defic Syndr; 2004 Jul; 36(3):876-8. PubMed ID: 15213573
    [No Abstract]   [Full Text] [Related]  

  • 28. Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?
    Frenkel LM; Mullins JI
    N Engl J Med; 2001 Feb; 344(7):520-2. PubMed ID: 11172196
    [No Abstract]   [Full Text] [Related]  

  • 29. Foscarnet activity on human immunodeficiency virus type 1 in the central nervous system.
    Delforge ML; Farber CM; De Leener F; Caroyer JM; Liesnard C; Van Vooren JP
    Clin Infect Dis; 1999 Apr; 28(4):931. PubMed ID: 10825078
    [No Abstract]   [Full Text] [Related]  

  • 30. Using non-nucleoside reverse transcriptase inhibitors in treating HIV disease: where are the therapeutic niches?
    Idemyor V
    J Natl Med Assoc; 2000 Feb; 92(2):99-101. PubMed ID: 10800301
    [No Abstract]   [Full Text] [Related]  

  • 31. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001.
    Panel on Clinical Practices for Treatment of HIV Infection
    HIV Clin Trials; 2001; 2(3):227-306. PubMed ID: 11590532
    [No Abstract]   [Full Text] [Related]  

  • 32. Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque.
    Stoddart CA; Galkina SA; Joshi P; Kosikova G; Moreno ME; Rivera JM; Sloan B; Reeve AB; Sarafianos SG; Murphey-Corb M; Parniak MA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4190-8. PubMed ID: 25941222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment.
    Bartlett JA; DeMasi R; Dawson D; Hill A
    J Infect Dis; 1998 Dec; 178(6):1803-5. PubMed ID: 9815239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of HIV-1 circular DNA as a surrogate marker for residual virus replication in patients with undetectable virus loads.
    Hauber I; Harrer T; Löw P; Schmitt M; Schwingel E; Hauber J
    AIDS; 2000 Nov; 14(16):2619-21. PubMed ID: 11101080
    [No Abstract]   [Full Text] [Related]  

  • 35. Adherence to triple therapy and viral load response.
    Low-Beer S; Yip B; O'Shaughnessy MV; Hogg RS; Montaner JS
    J Acquir Immune Defic Syndr; 2000 Apr; 23(4):360-1. PubMed ID: 10836763
    [No Abstract]   [Full Text] [Related]  

  • 36. Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.
    Holec AD; Mandal S; Prathipati PK; Destache CJ
    Curr HIV Res; 2017; 15(6):411-421. PubMed ID: 29165087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transient rebound of plasma HIV-1 RNA is not followed by repopulation of the lymphoid compartment with HIV-1-infected cells.
    Joos B; Fischer M; Opravil M; Ott P; Weber R; Cone RW
    AIDS; 2000 Apr; 14(6):752-4. PubMed ID: 10807203
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of costs of strategies for measuring levels of human immunodeficiency virus type 1 RNA in plasma by using Amplicor and Ultra Direct assays.
    Raboud JM; Seminari E; Rae SL; Harrigan PR; Hogg RS; Conway B; Sherlock C; Schechter MT; O'Shaughnessy MV; Montaner JS
    J Clin Microbiol; 1998 Nov; 36(11):3369-71. PubMed ID: 9774597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels.
    Sha BE; Johnson VA; Kendall MA; Haubrich R; Nokta M; Lamb K; Zackin RA; Nail CD; Currier JS
    AIDS; 2000 Apr; 14(6):746-8. PubMed ID: 10807200
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-HIV therapy.
    Geraci AP; Di Rocco A
    AIDS; 2000 Sep; 14(13):2059-61. PubMed ID: 10997418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.